
On Thursday, Eli Lilly released the results of its study of type 2 diabetes treatment tirzepatide, which will compete with Novo Nordisk's Ozempic.
These results were strong, says Sydbank Chief Equity Analyst Søren Løntoft Hansen.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app